Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 15,077,872	$ 7,076,651
Restricted cash	5,002,649	0
Marketable securities	44,371,615	0
Accounts receivable, net of allowances of $0 at September 30, 2017 and December 31, 2016, respectively	401,558	138,774
Prepaid and other current assets	920,008	1,900,493
Current assets related to discontinued operations	0	15,533,043
Total current assets	65,773,702	24,648,961
Property, plant and equipment, net	364,118	705,438
Other assets	1,417,439	1,582,209
Other assets related to discontinued operations	0	26,577,834
Total assets	67,555,259	53,514,442
Current Liabilities
Accounts payable	879,625	2,226,580
Accrued liabilities	10,135,600	2,659,433
Long-term debt, current	0	3,126,457
Notes payable, current	359,553	563,777
Due to PCT	0	1,681,594
Current liabilities related to discontinued operations	0	10,925,052
Total current liabilities	11,374,778	21,182,893
Notes payable	0	159,180
Long-term debt	0	2,524,897
Other long-term liabilities	3,200,154	389,858
Liabilities related to discontinued operations	0	5,791,134
Total liabilities	14,574,932	30,047,962
Commitments and Contingencies
Redeemable Securities - Non-Controlling Interests	0	19,400,000
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2017 and December 31, 2016	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,427,001 and 8,205,790 shares, at September 30, 2017 and December 31, 2016, respectively	9,427	8,206
Additional paid-in capital	433,006,780	410,372,049
Treasury stock, at cost; 11,080 shares at September 30, 2017 and December 31, 2016, respectively	(707,637)	(707,637)
Accumulated deficit	(378,947,243)	(404,788,809)
Accumulated other comprehensive loss	(28,717)	0
Total Caladrius Biosciences, Inc. stockholders' equity	53,332,710	4,883,909
Noncontrolling interests	(352,383)	(817,429)
Total equity	52,980,327	4,066,480
Liabilities and Equity, Total	$ 67,555,259	$ 53,514,442

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.